Amphista Therapeutics

The Next Generation in Targeted Protein Degradation Therapeutics

Business Model
B2B
Total Funding
$60.5M
Last Round
$53.0M Series BMar 2021
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Amphista Therapeutics develops next-generation targeted protein degradation medicines using its proprietary Targeted Glue technology. Unlike therapies that temporarily inhibit a disease-associated protein, Amphista's rationally designed degraders trigger the selective destruction and removal of pathogenic proteins, combining strengths of traditional PROTAC and molecular glue approaches to reach a wider tissue and indication scope. Based on Granta Park in the Cambridge, UK biopharma cluster, the company focuses on transforming the lives of patients with severe diseases.

Summary

Amphista Therapeutics is a Biotech company. It has raised $60.5M in total across 2 rounds, most recently a $53.0M Series B round in Mar 2021.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BMar 2021
$53.0M

Sign up to see all 2 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Amphista Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/amphista-therapeutics"><img src="https://indexed.vc/api/badge/company/amphista-therapeutics" alt="Amphista Therapeutics on Indexed.vc" width="260" height="76" /></a>